Reading a biotech's financials: R&D intensity and cash-to-market-cap

What replaces them: metrics about *spending quality* and *survival*. Is the money going into science or overhead? How long until the cash runs out? That is the real analysis.

Our worked example

Here is a simplified annual income statement for a fictional clinical-stage company, "NovaTx." All figures illustrative, in USD millions.

| Line item | Amount ($M) |

|---|---|

| Collaboration revenue | 20 |

| Research & development (R&D) expense | 180 |

| General & administrative (G&A) expense | 60 |

| Total operating expenses | 240 |

| Operating loss | (220) |

| Interest income | 15 |

| Net loss | (205) |

And a simplified balance sheet:

| Balance sheet item | Amount ($M) |

|---|---|

| Cash, equivalents & marketable securities | 500 |

| Total debt | 50 |

| Shares outstanding | 100 million |

| Share price | $12 |

Two definitions before we calculate. G&A covers salaries for management, legal, finance, rent: the cost of running the company. Collaboration revenue is cash from a partner (often big pharma) paying NovaTx to co-develop a drug. It is not product sales.

Calculation 1: R&D intensity

R&D intensity tells you what share of spending is going into the actual science versus keeping the lights on. Two common versions:

R&D as percent of total operating expense:

R&D-to-G&A ratio:

How to read it

For a clinical-stage biotech, high R&D intensity is usually a *good* sign. It means the company is spending on developing drugs, not on bloated administration.

As a rough benchmark, healthy clinical-stage biotechs often run R&D at roughly 65 to 80 percent of opex (industry-observed range, not a hard rule, as of 2025). NovaTx at 75 percent sits comfortably inside that.

A red flag: G&A creeping up while pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.View full definition → data stalls. If R&D intensity drops toward 50 percent without a clear reason (like commercial launch prep), ask why overhead is eating the budget.

Note: unlike a software firm, a biotech does *not* capitalize most R&D. Under both US GAAP and IFRS, research costs are expensed as incurred. So R&D hits the income statement directly. That is why losses look so large.

Calculation 2: Cash runway

Before market cap, calculate survival. Cash runway is how many months the company can operate before running out of money.

First, find the net cash burn: cash consumed by operations per period. A quick proxy is the operating loss adjusted for non-cash items, but for a simple pass we use the annual operating cash outflow. Assume NovaTx burns about $200M per year (close to its operating loss).

Thirty months, or about 2.5 years. That is the single most important number for a pre-revenue biotech.

The benchmark that moves stock prices

Investors want to see runway extending past the next major clinical readout (the moment trial results are announced). A company with a Phase 3 result due in 18 months and only 12 months of cash is in trouble: it will likely need to raise money at a weak price, diluting existing shareholders.

Rule of thumb (industry convention, not a law): analysts get nervous when runway drops below 12 months. NovaTx at 30 months is well positioned.

🎬 [VIDEO: "How Biotech Companies Are Valued" - youtube.com - plain-language walkthrough of valuing pre-revenue drug developers and why cash matters]

Calculation 3: Cash-to-market-cap

Market capitalization is the total value of the company's equity: share price times shares outstanding.

Cash-to-market-cap ratio:

How to read it

This ratio tells you how much of the company's value is just the cash in the bank versus the value the market assigns to the *pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.View full definition →* (the drugs in development).

At 42 percent, the market is valuing NovaTx's science at roughly the remaining 58 percent, about $700M.

Watch for the extreme case: when cash-to-market-cap approaches or exceeds 100 percent, the market is valuing the pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.View full definition → at zero or *negative*. This happens surprisingly often to beaten-down clinical-stage names after a trial failure. It can signal deep pessimism, or occasionally a mispriced opportunity. It is also a takeover trigger: acquirers sometimes buy such companies mainly for the cash and tax assets.

For a broader sense of sector valuations, the BioPharma sector data on Aswath Damodaran's NYU page is a free, respected reference for industry margins and multiples.

Calculation 4: Enterprise value

Enterprise value (EV) is the theoretical cost to buy the whole business: equity plus debt, minus cash (because the acquirer gets the cash).

Why EV matters more than market cap here

EV strips out the balance sheet and isolates what the market pays for the *operating business and pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.View full definition →*. NovaTx's $1.2B market cap overstates the pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.View full definition → value; the EV of $750M is the cleaner number.

When comparing two biotechs at the same trial stage, compare EV, not market cap. A company with a $1B market cap but $600M cash (EV $400M net of any debt) is a cheaper bet on the science than one with a $1B market cap and $100M cash (EV $900M), all else equal.

US versus Europe: financing context

The metrics are identical on both sides of the Atlantic; the financing environment differs.

• US: Deeper capital markets and a large specialist biotech investor base. Nasdaq is the dominant listing venue. US clinical-stage companies often carry longer cash runways because follow-on equity raises are more accessible (general industry observation, as of 2025).
• Europe: Historically thinner biotech equity markets, with more reliance on venture financing, non-dilutive grants (for example EU Horizon Europe funding), and partnerships with large pharma. European clinical-stage firms more frequently list on Nasdaq to reachreachThe number of unique people exposed to your message in a given period. Unlike impressions, reach counts each person once, no matter how often they see it.View full definition → US investors. Euronext and the London Stock Exchange host others.

Practical takeaway: a European clinical-stage biotech with a 30-month runway may be managing capital more conservatively precisely because raising fresh cash at home can be harder. Read runway in the context of where the company can actually get money.

Putting the four numbers together

For NovaTx: R&D intensity 75 percent (spending on science, good), runway 30 months (survives past likely readouts, good), cash-to-market-cap 42 percent (market credits the pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.View full definition → meaningfully), EV $750M (the real price of the science). That is a coherent, reasonably healthy clinical-stage profile.

Change one input, say the share price falls to $6 after weak trial data, and the story flips: market cap $600M, cash-to-market-cap 83 percent, EV $150M. The market has all but written off the pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.View full definition →. Same balance sheet, completely different signal.

Key Takeaways

• Losses are normal; burn and runway are the vital signs. Runway below 12 months is a common red flag; NovaTx's 30 months clears it comfortably.
• R&D intensity of roughly 65 to 80 percent of opex signals money going into science, not overhead. Falling intensity without a launch reason deserves scrutiny.
• Cash-to-market-cap near or above 100 percent means the market values the pipelinepipelineAll active sales opportunities across the stages of the sales process, together with their combined potential value and probability of closing.View full definition → at zero or less: deep pessimism, or a possible acquisition target.
• Use enterprise value, not market cap, to compare pipelines, because EV removes the distortion of cash and debt.
• Same metrics, different financing worlds: read US and European runways against the capital markets each company can realistically tap.

*This lesson is educational and not investment advice.*